
Neoadjuvant eftilagimod alfa, pembrolizumab, and radiotherapy produced an 81.1% 12-month DFS rate in high-risk, resectable soft tissue sarcoma.
In a recent Training Academy, experts discussed how to incorporate bispecific antibodies into patients with multiple myeloma.
In a recent Training Academy, experts discussed how to incorporate bispecific antibodies into patients with multiple myeloma.
about 3 years ago
Treatment Recommendations for Relapsed Multiple Myelomaabout 3 years ago
BTK Inhibitor Treatment Strategies in Chronic Lymphocytic Leukemiaabout 3 years ago
Treatment Updates and Key Highlights in Multiple Myeloma and CMLabout 3 years ago
Adverse Effect Management in Non–Small Cell Lung Cancer Treatment





